VP002SIAL

Applied Filters:

Keyword:'VP002SIAL'

facet content type:Technical Article

Showing 1-7 of 7 results for "VP002SIAL" within Site Content

Scalability Challenges of Viral Vector Manufacturing

Scaling up viral vector production using adherent cell culture systems is challenging. Learn how suspension cell culture systems benefit large-scale bioprocessing.

Bioreactor Process Development and Scale-Up for Transient Transfection-Based Lentivirus Manufacturing in Suspension Cell Culture

A step-by-step overview of suspension-based, transient transfection bioreactor process development and scaleup of lentivirus production.

Bioprocessing And Scale-Up Of Suspension HEK293 Cells For AAV Manufacturing

To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.

Can AAV Continue to Deliver the Promise of Gene Therapy?

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

Cell and Gene Therapy Manufacturing: Upstream Processing for AAV and Lentivirus Platforms

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

High Perf. Platforms for Lentiviral & AAV Mfg

Upstream gene therapy optimization maximizes viral vector titers; partner with technology experts for HEK293, HEK293T, and Sf9 cell solutions.

Protein Fingerprinting of a Viral Vector, AAV5

Method development for protein fingerprinting of AAV serotype 5 using both intact mass analysis and peptide mapping, to determine critical quality attributes for gene therapy, utilizing three different columns.